Bank of New York Mellon’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-417,539
| Closed | -$30.1M | – | 4282 |
|
|
2025
Q4 | $30.1M | Buy |
417,539
+35,711
| +9% | +$2.31M | 0.01% | 1303 |
|
|
2025
Q3 | $16.6M | Sell |
381,828
-1,332
| -0.3% | -$53.8K | ﹤0.01% | 1640 |
|
|
2025
Q2 | $10.9M | Buy |
383,160
+16,566
| +5% | +$494K | ﹤0.01% | 1853 |
|
|
2025
Q1 | $10.8M | Buy |
366,594
+3,577
| +1% | +$111K | ﹤0.01% | 1816 |
|
|
2024
Q4 | $10.6M | Buy |
363,017
+59,295
| +20% | +$2.48M | ﹤0.01% | 1902 |
|
|
2024
Q3 | $13.9M | Sell |
303,722
-60,231
| -17% | -$2.61M | ﹤0.01% | 1767 |
|
|
2024
Q2 | $14.9M | Buy |
363,953
+115,676
| +47% | +$3.32M | ﹤0.01% | 1745 |
|
|
2024
Q1 | $6.34M | Sell |
248,277
-10,371
| -4% | -$163K | ﹤0.01% | 2200 |
|
|
2023
Q4 | $2.34M | Buy |
258,648
+6,616
| +3% | +$44.2K | ﹤0.01% | 2747 |
|
|
2023
Q3 | $1.61M | Sell |
252,032
-2,395
| -0.9% | -$20.6K | ﹤0.01% | 2927 |
|
|
2023
Q2 | $2.82M | Buy |
254,427
+22,779
| +10% | +$286K | ﹤0.01% | 2646 |
|
|
2023
Q1 | $3.56M | Buy |
231,648
+35,555
| +18% | +$782K | ﹤0.01% | 2485 |
|
|
2022
Q4 | $4.35M | Buy |
196,093
+20,293
| +12% | +$303K | ﹤0.01% | 2416 |
|
|
2022
Q3 | $2.87M | Buy |
175,800
+19,046
| +12% | +$364K | ﹤0.01% | 2611 |
|
|
2022
Q2 | $2.28M | Buy |
156,754
+20,133
| +15% | +$300K | ﹤0.01% | 2759 |
|
|
2022
Q1 | $2.52M | Buy |
136,621
+719
| +0.5% | +$12.2K | ﹤0.01% | 2809 |
|
|
2021
Q4 | $3.23M | Buy |
135,902
+15,409
| +13% | +$368K | ﹤0.01% | 2704 |
|
|
2021
Q3 | $2.97M | Buy |
120,493
+26,077
| +28% | +$567K | ﹤0.01% | 2772 |
|
|
2021
Q2 | $2.33M | Buy |
94,416
+9,965
| +12% | +$232K | ﹤0.01% | 2895 |
|
|
2021
Q1 | $1.84M | Buy |
84,451
+21,177
| +33% | +$518K | ﹤0.01% | 2967 |
|
|
2020
Q4 | $1.61M | Buy |
63,274
+16,639
| +36% | +$485K | ﹤0.01% | 2967 |
|
|
2020
Q3 | $1.31M | Buy |
+46,635
| New | +$1.35M | ﹤0.01% | 2952 |
|
Other funds holding RNAM
Bank of New York Mellon's RNAM Position: Q1 2026 in Review
Bank of New York Mellon sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 417,539 shares — an estimated $30.1M sold.
Bank of New York Mellon first reported a position in RNAM in Q3 2020 and held it in 22 quarters. The position peaked at $30.1M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Bank of New York Mellon reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Bank of New York Mellon sold 417,539 Avidity Biosciences shares in Q1 2026, an estimated $30.1M.
- Bank of New York Mellon first reported a position in Avidity Biosciences in Q3 2020 and held it in 22 quarters.
- Bank of New York Mellon's Avidity Biosciences position peaked at $30.1M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Bank of New York Mellon's 13F filing for Q1 2026, filed 5 May 2026.